Transgenic SHIP2 animals and in vivo screening methods

Abstract

Transgenic animals comprising an alteration in the endogenous SH2 domain containing inositol 5-phosphatase (SHIP2), including both knock-in, knockouts, and knock-in/knockouts are described, as well as in vivo methods for identifying inhibitors of SHIP2. Such inhibitors are potential therapeutics for treatment of obesity and/or glucose intolerance resulting from a high fat diet.

Dependencies are inferred from the claim text.